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Abstract
Background: The role of human papillomavirus (HPV) in malignant and non-malignant genital diseases in women
is well known and the corresponding epidemiological burden has been widely described. However, less is known
about the role of HPV in anal, penile and head and neck cancer, and the burden of malignant and non-malignant
HPV-related diseases in men. The objective of this review is to estimate the epidemiological burden of HPV-related
cancers and non-malignant diseases in men in Europe.
Methods: The annual number of new HPV-related cancers in men in Europe was estimated using Eurostat
population data and applying cancer incidence rates published by the International Agency for Research on
Cancer. The number of cancer cases attributable to HPV, and specifically to HPV16/18, was calculated based on the
most relevant prevalence estimates. The annual number of new cases of genital warts was calculated from the
most robust European studies; and latest HPV6/11 prevalence estimates were then applied. A literature review was
also performed to retrieve exhaustive data on HPV infection at all anatomical sites under study, as well as
incidence and prevalence of external genital warts, recurrent respiratory papillomatosis and HPV-related cancer
trends in men in Europe.
Results: A total of 72, 694 new cancer cases at HPV-related anatomical sites were estimated to occur each year in
men in Europe. 17,403 of these cancer cases could be attributable to HPV, with 15,497 of them specifically
attributable to HPV16/18. In addition, between 286,682 and 325,722 new cases of genital warts attributable to
HPV6/11were estimated to occur annually in men in Europe.
Conclusions: The overall estimated epidemiological burden of HPV-related cancers and non-malignant diseases is
high in men in Europe. Approximately 30% of all new cancer cases attributable to HPV16/18 that occur yearly in
Europe were estimated to occur in men. As in women, the vast majority of HPV-positive cancer in men is related
to HPV16/18, while almost all HPV-related non-malignant diseases are due to HPV6/11. A substantial number of
these malignant and non-malignant diseases may potentially be prevented by quadrivalent HPV vaccination.
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Background
Human papillomavirus (HPV) has been established as a
necessary cause of cervical cancer. Around 50% of
women become infected with HPV by age 20-30 years
[1] and persistent infection can lead to the development
of malignant and non-malignant diseases. Indeed, the
role of HPV in cervical cancer, in premalignant lesions
of the cervix, vulva and vagina, and in external genital
warts is well known, and the corresponding epidemiolo-
gical burden in women has been widely described [2-6].
However, less is known about the natural history of
HPV infection in men and the role of HPV in penile,
anal and head and neck cancers.
As early as 1983, it was suggested that a subset of can-
cers of the oral cavity and larynx may be caused by HPV
[7]. The juxtaposition between the squamous cell
epithelium and the lymphatic tissue in the oropharynx,
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share similarities with the transformation zone of the
cervix, and might therefore be areas that are highly sus-
ceptible to HPV infection.
In 2007 the International Agency for Research on
Cancer (IARC) concluded that there was “sufficient” evi-
dence to support the carcinogenicity of HPV in the
penis, anus, oral cavity, oropharynx and tonsils, and
“limited” evidence to support the carcinogenicity of
HPV in the larynx [8]. This statement was confirmed by
an IARC Monograph Working Group in 2011 [9].
In addition to cancer, HPV is responsible for some
non-malignant diseases. Indeed, the great majority of
genital warts, recurrent respiratory papillomatosis and
oral papillomas are attributable to HPV, mostly HPV6/
11 [10-12].
All HPV-induced cancers and non-malignant diseases
are necessarily preceded by HPV infection. However, lit-
tle is known about the prevalence of HPV infection and
related diseases in men at different anatomical sites.
Therefore the purpose of this review is to estimate the
epidemiological burden of HPV-related cancers and
non-malignant diseases, as well as the prevalence of
HPV infection, in men in Europe.
Methods
Literature review
A literature review was performed to retrieve exhaustive
European data on trends of HPV-related cancers, inci-
dence and prevalence of genital warts, recurrent respira-
tory papillomatosis and HPV infection. Searches were
conducted on MEDLINE and included articles published
from January 1990 through November 2010.
Articles containing data on the trends of HPV-
related cancers were obtained by combining the search
terms “HPV”, “human papillomavirus”, “cancers” and
“trends”. Those with data on the prevalence and inci-
dence of genital warts and recurrent respiratory papil-
lomatosis were obtained by using different
combinations of the following search terms “genital
warts”, “anogenital warts”, “external warts”, “condy-
loma/condylomata acuminata”, “incidence” and “preva-
lence"; and “papillomatosis”, “incidence” and
“prevalence”, respectively. Finally, articles containing
data on the incidence and prevalence of HPV infec-
tions were obtained by combining the search terms
“HPV”, “human papillomavirus”, “infection”, “oral cav-
ity”, “oropharynx”, “larynx”, “anus”, “penis”, “men” and
“males”.
Only articles referring to the populations of the 26
European countries included in this review were consid-
ered. Articles identified from the reference lists of
retrieved publications were also included.
Estimation of the annual number of new cancer cases
For the purposes of this review, cancers occurring at
three anatomical sites were considered HPV-related, as
HPV infection may play a role in their development: a
subset of head and neck cancers (International Classifi-
cation of Diseases 10
th Revision (ICD-10) codes C01-
C02, C03-C06, C09, C10, C12, C13, C14 and C32,
(Table 1)), anal cancer (C21) and penile cancer (C60).
All epidemiological cancer data described in this review
refer exclusively to these selected cancers and cancer
sites, which are hereafter referred to as “HPV-related”.
To estimate the mean annual number of new HPV-
related cancer cases in men in Europe, sex- and age-
specific annual cancer incidence rates by country,
extracted from Volume IX of the Cancer Incidence in
Five Continents (CI5) database, were applied to the
respective Eurostat country male population estimates
[13]. The age-specific estimated numbers of new male
cancer cases were summed up to obtain the overall
number of expected cases in 2008 for each selected
country:
85+ 
0
nbof newcases2008 =
AIR ∗ (per 100,000) × population ∗∗ (2008)
100,000
*age- and sex-specific annual incidence rate
**age- and sex-specific population
The expected numbers of new cancer cases of all
selected countries were then summed up to estimate the
overall European Burden.
The number of cancer cases that may have been attri-
butable to HPV and specifically to HPV16/18 was then
evaluated by applying cancer-specific HPV prevalence
and HPV16/18 prevalence estimates, respectively,
extracted from the most relevant published data. When
available, European data were used. When European
data were not available, worldwide data were used.
For comparison purposes, the same methods were also
used to estimate the epidemiological burden of HPV-
related cancers in women in Europe. HPV-related can-
cer sites in women are the cervix uteri (ICD-10 code
C53), vagina (C52), vulva (C51), anus (C21) and a subset
of head and neck cancers (C01-C02, C03-C06, C09, C10,
C12, C13, C14 and C32).
The CI5 database, available on the IARC website [14],
contains worldwide data on cancer incidence rates by
ICD-10 codes, obtained from cancer registries that meet
the IARC’s quality criteria [15]. The registries are either
regional or national, depending on the country. The
data included in Volume IX were collected between
1998 and 2002.
Only cancer registries that meet the IARC’sq u a l i t y
criteria, i.e., that have reliable national or regional can-
cer registry data, are included in the CI5 database. We
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(Greece, Hungary, Luxemburg, and Romania) were not
included in the CI5 database as they did not have reli-
able registry data. Three European countries (Iceland,
Norway and Switzerland) that do not belong to the Eur-
opean Union were also selected as they are located in
the same geographical area and share similarities in
terms of way of life. Hence a total of 26 European coun-
tries were included in this analysis.
Information in the CI5 database originated from
national cancer registries for Austria, Bulgaria, Cyprus,
the Czech Republic, Denmark, Estonia, Finland, Iceland,
Ireland, Latvia, Lithuania, Malta, the Netherlands, Nor-
way, Slovenia, Slovakia and Sweden. Regional cancer
registry data were available for Belgium, France, Ger-
many, Italy, Poland, Portugal, Spain, Switzerland and the
United Kingdom.
To ensure that national populations were adequately
represented in countries where only regional cancer
registries exist, the geographical coverage and distribu-
tion of these registries was assessed.
Estimation of the annual number of new cases of genital
warts
To estimate the annual number of incident cases of gen-
ital warts, two European publications which provided,
based on their design, the most robust incidence data
for Europe, were selected [16,17]: both are retrospective
cohort studies carried out in databases, including very
large samples of routinely collected data. We extrapo-
lated the value from each publication to all 26 European
countries to provide a range of estimated new cases of
genital warts that are expected to occur yearly in men
in Europe. The German incidence data [17] were used
to estimate the lower value, and the data from the Uni-
ted Kingdom [16] the upper value. The estimated preva-
lence of HPV6/11 in genital warts was then applied
based on the only two European publications identified
on the subject [10,12].
For comparison purposes the same method was used
to estimate the epidemiological burden of HPV-related
genital warts in women in Europe.
Results
HPV-related cancers
Head and neck cancers
Head and neck cancers generally first occur between 30
and 35 years of age among men in Europe. The inci-
dence then steadily increases with a peak in the sixth
decade of life for oropharyngeal cancer and cancer of
the oral cavity, and in the seventh decade of life for lar-
yngeal cancer (Figure 1).
The overall age-standardised incidence rates of the
subset of head and neck cancers included in this review,
irrespective of HPV status, ranged from 5.6 (in Cyprus)
to 33.0 (in France) per 100,000 man-years in Europe
(CI5 Volume IX) (Figure 2). They were characterised by
a strong incidence gradient, with rates increasing from
5.6 to 8.2 per 100,000 man-years in Cyprus and the
Nordic countries (Sweden, Finland, Norway and Iceland)
up to 27.0-33.0 per 100,000 man-years in Spain, the Slo-
vak Republic and France.
Among the included subset of head and neck cancers,
laryngeal cancer had the highest incidence in Europe
(age-standardised incidence rates ranging from 2.0 per
Table 1 List of included head and neck sites and subsites
Site description ICD-10 Code
Oral cavity
Tongue (incl. base of the tongue, other parts of the tongue) C01-C02
Mouth (incl. gum, floor of the mouth, palate) C03-C06
Pharynx
Tonsil C09
Oropharynx C10
Piriform sinus C12
Hypopharynx C13
Pharynx unspecified (incl. Waldeyer’s ring, overlapping lesion of lip, oral cavity and pharynx) C14
Larynx C32
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Figure 1 Incidence of head and neck cancers, irrespective of
HPV status, in men in Europe by age group.
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Page 3 of 18100,000 man-years in Sweden to 13.3 per 100,000 man-
years in Spain), higher than that of cancer of the oral
cavity (1.8 per 100,000 man-years in Cyprus to 10.7 per
100,000 man-years in France) and oropharynx (0.6 per
100,000 man-years in Cyprus to 14.1 per 100,000 man-
years in France).
Moreover, the incidence of cancer at different head
and neck sites did vary by geographical region. For
example, cancer of the oral cavity was predominant in
the Nordic countries, while oropharyngeal cancer was
most common in Western and Central European coun-
t r i e s( F r a n c e ,G e r m a n y ,S w i t z e r l a n d ,A u s t r i a ,S l o v e n i a
and Slovakia). In the remaining European countries, lar-
yngeal cancer was the most common, with incidence
rates representing up to 50% of head and neck cancers
in several countries (Bulgaria, Poland, Italy, Spain,
Malta) (Figure 3a-c).
Within the included subset of head and neck cancers,
a total of 67,354 (bounds: 63,443-71,292) new cases
were estimated to occur in men in Europe every year
(cancer of the oral cavity: 20,133 cases, oropharyngeal
cancer: 20,433 cases, laryngeal cancer: 26,788 cases).
Assuming an HPV prevalence of 16.0% for cancer of the
oral cavity, 28.2% for oropharyngeal cancer (except
hypopharyngeal cancer where HPV prevalence is the
same as for laryngeal cancer) and 21.3% for laryngeal
cancer [18], a total of 14,098 (bounds: 11,455-17,077) of
these cases would actually be attributable to HPV (3,221
cancers of the oral cavity, 5,171 oropharyngeal cancers
and 5,706 laryngeal cancers) (Table 2).
HPV16/18 are the predominant types in HPV-positive
head and neck cancers. They are thought to be present
in 68.2% and 34.1%, respectively, of HPV-positive can-
cers of the oral cavity, 86.7% and 2.8% of HPV-positive
oropharyngeal cancers and 69.2% and 17.0% of HPV-
positive laryngeal cancers [18]. Accordingly, a total of
12,707 new head and neck cancer cases were expected
to be attributable to HPV16/18 each year in men in
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Figure 2 Age-standardised incidence rate (ASR) of a subset of head and neck cancers irrespective of human papillomavirus status.
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Figure 3 Distribution of head and neck cancers by anatomical site in men in Europe. a. Distribution of head and neck cancers by
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yngeal cancers and 4,919 laryngeal cancers) (Table 2).
Three European studies reported an increasing inci-
dence trend in the included subset of head and neck
cancers in men. In the United Kingdom, the incidence
of squamous cell carcinoma of the oral cavity and oro-
pharynx in men rose by 51% between 1989 and 2006
[21]. In Sweden, an increase of 2.6% in the incidence of
tonsillar cancer in men was observed in each year
between 1960 and 2003 [22,23].
Anal cancer
Anal cancer generally first occurs between 30 and 35
years of age among men in Europe. The incidence then
steadily increases with age in all European countries
(data not shown). Age-standardised rates of anal cancer
ranged from 0.2 (in Cyprus, Finland and Iceland) to 0.7
per 100,000 man-years (in the United Kingdom) (CI5
Volume IX) (Figure 4).
A total of 2,162 (bounds: 1,722-2,620) new anal cancer
cases were estimated to occur each year in men in Eur-
ope, irrespective of HPV status. Given the overall HPV
prevalence of 84.2% (95%CI: 81.5%-86.9%) [19] in anal
cancer, 1,821 (bounds: 1,403-2,277) cases in men in Eur-
ope were estimated to be attributable to HPV. The pre-
valence of HPV16/18 in HPV positive anal cancer cases
has been estimated at 87.1% and 6.2% respectively [19].
After applying this prevalence, 1,699 of cases were esti-
mated to be attributable to HPV16/18 (Table 2).
Several studies have reported an increasing trend in
the incidence of anal cancer in men in Europe over
time. In Southeast England the age-standardised inci-
dence rates in men increased from 0.79 per 100,000
man-years in 1960-1964 to 1.06 in 2000-2004. The Scot-
tish Cancer Registry recorded an increase in the age-
standardised incidence rates of anal squamous cell carci-
noma in men, from 0.14 per 100,000 man-years in the
late 1970s to 0.37 in the late 1990s, with a peak of 0.44
in 1993-1997 [24]. Similar trends have been seen in
other European countries: in Denmark, the annual inci-
dence rates in men rose from 0.25 per 100,000 man-
years in 1958-1962 to 0.38 in 1983-1987 according to
Frisch et al. [25] and the age standardised incidence rate
of anal cancer in men increased from 0.45 per 100,000
man-years in 1978-1982 to 0.80 in 2003-2008 according
t oN i e l s e ne ta l .[ 2 6 ] .I nS w e d e n ,G o l d m a ne ta l .[ 2 7 ]
recorded an annual increase of 4.6% in incidence rates
among men, from 0.52 per 100,000 man-years in 1970-
1974 to 0.84 in 1980-1984. Increasing trends have also
been reported from the Netherlands [28].
Penile cancer
In Europe, penile cancer tends to be diagnosed at age
30-35 years onwards, with an incidence peak in the
seventh decade of life (data not shown). Age-standar-
dised rates of penile cancer in men in Europe, irrespec-
tive of HPV status, ranged between 0.5 (in Finland) and
1.1 per 100,000 man-years (in Denmark, Portugal and
Iceland) (CI5 Vol. IX) with substantial geographical var-
iations (Figure 5).
A total of 3,178 (bounds: 2,623-3,751) new penile cancer
cases were estimated to occur annually in Europe.
Table 2 Expected annual number of new human papillomavirus (HPV)-related cancer cases in men in Europe
a
Cancer sites
(ICD 10
code)
Expected number of new
cancer cases, irrespective of
HPV status
(bounds)
HPV
prevalence
by site (%)
(95%CI)
Expected number of
new cancer cases
attributable to HPV
(bounds)
Prevalence of HPV 16/
18 in HPV-positive
cancers (%)
Expected number of new
cancer cases attributable
to HPV16/18
Head and
neck
Oral cavity
b
Oropharynx
c
Larynx (C32)
67,354
(63,443-71,292)
20,133
(18,768-21,514)
20,433
(19,651-21,776)
26,788
(25,210-28,382)
16.0
(13.4-18.8)
28.2
d
(24.4-32.2)
21.3
(18.5-24.3)
[18]
14,098
(11,455-17,077)
3,221
(2,515-4,045)
5,171
(5030-5311)
5,706
(4,664-6,897)
68.2/34.1
86.7/2.8
69.2/17.0
12,707
3,221
4,567
4,919
Anus (C21) 2,162
(1,722-2,620)
84.2
(81.5-86.9)
[19]
1,821
(1,403-2,277)
87.1/6.2 1,699
Penis (C60) 3,178
(2,623-3,751)
46.7
(42.0-51.3)
[20]
1,484
(1,102-1925)
60.2/13.4 1,091
Total 72,694
(67,957-77,470)
17,403
(14,049-21,161)
15,497
ICD International Classification of Diseases, CI confidence interval
a 26 European countries
b Includes tongue (C01-02), mouth (C03-06), and also includes base of the tongue, which actually belongs to the oropharynx
c Includes tonsil (C09), other oropharynx (C10), hypopharynx (C12-13) and pharynx unspecified (C14)
d Except hypopharynx (C12-13), where HPV prevalence is the same as in laryngeal cancer (C32)
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42.0%-51.3%) and a specific HPV16/18 prevalence of
60.2% and 13.4% respectively among HPV-positive cancers
[20], 1,484 (bounds: 1,102-1,925) penile cancer cases were
estimated to be attributable to HPV, with 1,091 of those
specifically attributable to HPV16/18 (Table 2).
Increasing trends have been reported in the Nether-
lands, where one study noted a significant increase in
the 3-year moving average incidence rate of penile squa-
mous cell carcinoma between 1989 and 2006, with an
estimated annual percentage of change of 1.3% [29].
HPV-related non-malignant diseases
Genital warts
Genital warts represent a non-malignant disease affect-
ing anogenital sites. In men genital warts may occur on
the penis, anus, urethra, perianal skin and scrotum.
Most reports in the scientific literature did not indicate
the exact localisation of warts, and instead combined all
localisations into one group.
Prevalence Three studies provided data on the preva-
lence of genital warts in the general male population in
Europe [30-32]. The lowest prevalence was reported in
Spain (0.2%) [30], while the highest numbers were
recorded in a cohort of 432 Finnish conscripts (5.6%)
[31] (Table 3).
Other studies evaluated the prevalence of genital warts
in high-risk populations [37-40]. Prevalence ranged from
2.5% in male sex partners of women with cervical
intraepithelial neoplasia (CIN) in the Netherlands [37],
to 58% among men who have sex with men (MSM) in
Greece [38] (Table 4).
Incidence Six studies [16,17,30,33,34,36] provided inci-
dence data of new cases for men in Europe, ranging
from 136 per 100,000 man-years in Spain [30] to 294
per 100,000 man-years in Sweden [36]. When
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Figure 4 Age-standardised incidence rate (ASR) of anal cancer irrespective of human papillomavirus status in men in Europe.
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Page 7 of 18considering new and recurrent cases incidence rates
could even reach 319 per 100,000 man-years [33,34].
T h em o s tr o b u s td a t ao nt h ei n c i d e n c eo fg e n i t a l
warts come from Germany [17] and the United King-
dom [16]: Based on these studies, a lower incidence
estimate of 147.6 per 100,000 man-years and an upper
estimate of 167.7 per 100,000 man-years were
extracted, and so new annual genital wart cases in men
in Europe were estimated to range between 335,301
and 380,961. Assuming an HPV6/11 prevalence in gen-
ital warts of 85.5% [10,12], between 286,682 and
325,722 of these cases were estimated to be attributa-
ble to HPV6/11.
Recent data on genital warts rates seen at GUM
clinics are available at Health Protection Agency web-
page: the incidence of genital warts in men increased
from 148.5 per 100,000 in 2006 to 160.5 per 100,000 in
2010 [41].
Recurrent respiratory papillomatosis
European data on the incidence of recurrent respiratory
papillomatosis are very scarce. The only available data
were reported from Denmark where two studies
reported similar incidence rates: 0.38 cases per 100,000
for the period 1968-1984 [42] and 0.35 per 100,000 for
the period 1974-1999 [43]. However there was no infor-
mation about sex-specific incidence.
HPV infection
HPV infection in the oral cavity and oropharynx
Five European studies provided data about the prevalence
of oral cavity and oropharyngeal HPV infections in men.
Three of them measured the prevalence of all HPV types
in the oral mucosa of cancer-free men. Eike et al. [44] and
Van Dornuum et al. [45] found a prevalence of 0% in the
oral mucosa of almost 100 men, while in the Finnish
Family Study prevalence was 18% among 131 husbands of
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Figure 5 Age-standardised incidence rate (ASR) of penile cancer irrespective of human papillomavirus status in men in Europe.
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Page 8 of 18pregnant women tested with nested PCR [46]. The two
remaining studies evaluated high-risk HPV prevalence and
found a 3.8% prevalence in 26 healthy adult volunteers,
from whom samples had been taken at three different sites
of the oral cavity [47], and 14.5% in the saliva of 69 male
odonto-stomatology attendees without oral pathologies,
aged 4-77 years [48]. In all studies HPV detection was car-
ried out by PCR (Table 5).
Anal HPV infection
Six European studies analysed the prevalence of anal
HPV infections. All included cancer-free subjects belong-
ing to presumed high-risk groups for HPV infection,
such as MSM, HIV-positive men, sexually-transmitted
disease (STD) clinic attendees and heterosexual men
with multiple sexual partners. The overall prevalence of
anal HPV infection in these high-risk groups ranged
between 15.3% in a sample of 85 male STD clinic atten-
dees [49] and 94.1% among 17 HIV-positive MSM [49].
Anal HPV prevalence in HIV-positive MSM and HIV-
positive heterosexual men ranged from 64.7% [40] to
94.1% [50] and 46,0% [51] to 68.2% [52], respectively.
HPV prevalence in HIV-negative MSM was evaluated in
one study to be 32.8% [40] (Table 6).
Penile HPV infection
Twenty-three European studies provided information
on the prevalence of penile HPV infections in more
Table 3 Studies reporting on the incidence and prevalence of genital warts in general male populations in Europe
a
Author, year,
country
Population Sample
size
Design Incidence/100,000 95%CI Prevalence
(%)
95%
CI
Castellsagué, 2010
Spain [30]
General Retrospective
(medical
records)
136 0.2
Simms, 1997
UK [33]
GUM clinic attendees Prospective First occurence + recurrent
cases
65 (1971)
319 (1994)
ND
Cassell, 2006
UK [34]
General practice + GUM clinic
attendees
Retrospective
cohort
First occurence + recurrent
cases 307.6
(305.5-
309.8)
ND
Kraut, 2010
Germany [17]
>
14,000,000
Retrospective
cohort
144.57 (2005)
147.95 (2006)
(141.10-
148.09)
(144.48-
151.48)
ND
Fenton, 2001
UK [35]
General 4,500 Survey Cumulative incidence (self
reported)
360
(310-420) ND
Persson, 1996
Sweden [36]
General 32,774 Prospective 294 (207-372) ND
Hippeläinen, 1993
Finland [31]
Finnish conscripts 432 Cross-sectional ND 5.6 (3.4-
7.7)
Kataoka, 1991
Sweden [32]
Sweden 108 Cross-sectional ND 1.9 (0-
4.4)
Desai, 2011
UK [16]
General practice + GUM clinic
attendees
Retrospective
cohort
168 ND
CI confidence interval, GUM Genitourinary medicine, ND no data
a 26 European countries
Table 4 Studies reporting on the prevalence of genital warts in high-risk male populations in Europe
a
Author Country Population Design Prevalence (%) 95%CI
Kyriakis, 2005 [38] Greece 3667HS
856 MSM
211 IDU (HS+MSM)
Cross-sectional, hospital based 53 HS
58 MSM
51 IDU
(51.4-54.6)
(55.1-61.7)
(44.0-57.4)
Van der Snoek, 2003 [40] The Netherlands 258 MSM
241 HIV-
17 HIV+
Cross-sectional 27 (21.6-32.4)
Bleeker, 2002 [37] The Netherlands 119 male sex partners of women with CIN Prospective 2,5 (0.31-5.30)
Svare, 2002 [39] Denmark 261 STD clinic attendees Prospective 25 (19.7-30.1)
HS heterosexual, MSM men who have sex with men, IDU intravenous drug user, CI confidence interval, CIN cervical intraepithelial neoplasia, STD sexually
transmitted disease
a 26 European countries
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Page 9 of 18than 4,300 men. The majority of the study subjects
belonged to high-risk groups (HIV-positive men,
MSM, partners of women with CIN and STD clinic
attendees). The overall HPV prevalence ranged from
2.2% (95%CI: 0-6.4) in the semen of 46 husbands of
women with HPV-related genital lesions [53], to 72.9%
(95%CI: 65.8-79.3) in a report on male partners of
women with CIN [54].
One study [55], including 947 men with HPV-related
lesions or HPV-positive partners, compared samples at
different anatomical sites of the penis as well as semen
samples. HPV prevalence was highest on the penile
shaft (58.3%), followed by the glans/corona (43.3%), ure-
thra (31.0%) and semen (23.9%) (Table 7).
Discussion
Using different data sources and extrapolation methods,
this review showed that the overall estimated epidemio-
logical burden of HPV-related cancers and non-malig-
nant diseases is high among men in Europe. In addition
to malignant diseases, which include a subset of head
and neck cancers and anal and penile cancers, non-
malignant diseases such as genital warts and recurrent
respiratory papillomatosis are also associated with HPV.
Table 5 Studies reporting head and neck human papillomavirus (HPV) infection in cancer-free men in Europe
a
Author,
year,
country
Sample types Population Sample
size
Age
(years)
Sampling techniques and
detection methods
HPV (%)
Any 95%
CI
High-
risk
95%
CI
Montaldo
2007
Italy [48]
Saliva Odonto-
stomatology attendees, non-
diseased for oral pathology
69 4-77 Specimen
PCR
ND 14.5 (7.17-
25.04)
Kujan 2006
UK [47]
Three different sites
in the oral cavity
Healthy volunteers 26 > 18 Brushing
PCR
ND 3.8 (0.10-
19.64)
Rintala 2005
Finland [46]
Oral mucosa Husbands of pregnant women
(Finnish Family Study)
131 Brushing
nested PCR
18 (11.5-
24.5)
Eike 1995
Denmark [44]
Oral mucosa Patients with unrelated diseases
and their relatives
31 20-79 Smear
PCR
00
Van
Doornum,
1992 [45]
Tongue and buccal
mucosa
Men with multiple heterosexual
partners
65 mean
age: 38
Swabs
PCR
00
ND no data, CI confidence interval
a 26 European countries
Table 6 Studies reporting anal human papillomavirus (HPV) infection in cancer-free men in Europe
a
Author, year Country Population Sample size Sampling techniques and
detection methods
HPV (%)
Any 95%CI
Van der Snoek,
2003 [40]
The
Netherlands
MSM
HIV+ and HIV-
258
(17 HIV+, 241
HIV-)
Swabs
PCR + LiPA
64.7 (HIV+)
32.8 (HIV-)
(38.33-85.79)
(27.06-38.94)
Pierangeli, 2008
[56]
Italy MSM and
HS (HIV+ and HIV-)
61
(36 HIV+,
25 HIV-)
Anal brushing
PCR
81.6 (HIV+)
68.0 (HIV-)
(63.98-91.81)
(46.50-85.05)
Sirera, 2006 [52] Spain HIV+ men
(MSM and HS)
74
(52 MSM
22 HS)
Cytobrush
PCR
82.6 (MSM)
68.2 (HS)
(69.67-91.77)
(45.13-86.14)
Piketty, 2003 [51] France HIV+ men
(MSM and HSiDU)
118
(67 MSM, 50
HSiDU)
Swabs
PCR
85.1(MSM)
46.0 (HSiDU)
(74.26-92.60)
(31.81-60.68)
Van Doornum,
1994 [49]
The
Netherlands
STD clinic attendees 85 Cotton swabs or wooden spatula 15.3 (8.40-24.73)
Löwhagen, 1999
[50]
Sweden STD clinic attendees (HIV+
and HIV- MSM)
30
(17 HIV+,
13 HIV-)
Cotton swabs
PCR
76.7
94.1 (HIV+)
53.8 (HIV-)
(61.5-91.8)
(82.9-100.0)
(26.7-80.9)
CI confidence interval, MSM men who have sex with men, STD sexually transmitted disease, HS heterosexual, HSiDU heterosexual intravenous drug user, STD
sexually transmitted disease
a 26 European countries
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Page 10 of 18Table 7 Studies reporting penile human papillomavirus (HPV) infection in cancer-free men in Europe
a
Author Country Anatomical site(s) Population Sample
size
Sampling
techniques and
detection methods
HPV (%)
Any 95%CI High-
risk
95%CI
Bleeker 2005
[54]
The
Netherlands
Glans, corona, frenulum
and prepuce
Partners of women with CIN 181 Cervex brush
GP5+/6+ PCR
72.9 (65.8-79.3) 58.5 (51.0-79.3)
Kjaer 2005
[57]
Denmark Glans and corona Danish soldiers 337 Penile swabs
PCR
33.8 (28.8-39.2)
Sirera 2006
[52]
Spain Coronal sulcus, glans and
urethra distal
HIV+ men
(MSM and HS)
74
(52 MSM
22 HS)
Cytobrush
PCR
38
(MSM)
32 (HS)
(25-53)
(14-55)
Van der
Snoek 2003
[40]
The
Netherlands
Coronal sulcus STD clinic attendees; MSM HIV+ and HIV- 258
17HIV+
241 HIV-
Dry swab
PCR + LiPA
23.5
(HIV+)
15.8
(HIV-)
(6.81-49.9)
(11.4-21.0)
Bleeker 2002
[37]
The
Netherlands
Glans, corona, frenulum
and prepuce
Partners of women with CIN 119 Cervex brush
GP5+/6+ PCR
59.0 (49.4-67.8) 55.4 (46.1-67.8)
Svare 2002
[39]
Denmark Glans, corona, shaft,
scrotum and perianus
STD clinic attendees 198 Scrapping plus pre-
wetted swabs
GP5+/6+ PCR
45.0 (37.9-52.2) 18.6 (12.5-52.2)
Wikstrom
2000 [58]
Sweden Glans, corona, shaft,
scrotum and perianus
STD clinic attendees 235 Scrapping plus pre-
wetted swabs
GP5+/6+ PCR
20.4 (15.3-25.6) 12.8 (8.5-17.0)
Van
Doornum
1994 [49]
The
Netherlands
Corona, urethra, anus and
rectum
HS STD clinic attendees 85 Cotton swab/
wooden spatula
PCR
28.2 (19.0-39.0)
Forslund
1999 [59]
Sweden Urethra Military conscripts and adolescent clinic attendees 138 Prewetted brush
PCR
8.7 (4.6-14.7)
Hippelainen
1993 [31]
Finland Glans, prepuce, sulcus,
urethral meatus and
urethra
Finnish conscripts 285 Prewetted brush
PCR
16.5 (12.4-21.3)
Franceschi
2002 [60]
Spain Glans, corona, and
urethra
Husbands of women with invasive cervical cancer 84 Cotton tipped
Swabs
PCR
11.9 (5.9-20.8) 1.2 (0.0-20.8)
Husbands of women with cervical carcinoma in situ 102 21.6 (14.0-30.8) 6.9 (2.8-30.8)
Husbands of control women 168 3.6 (1.3-7.6) 1.8 (0.4-7.6)
Wikstrom
1991 [58]
Sweden Corona, prepuce, and
urethral meatus
STD clinic attendees, men with no history of genital
warts
135 PCR 13.3 (8.1-59.1)
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8Table 7 Studies reporting penile human papillomavirus (HPV) infection in cancer-free men in Europe
a (Continued)
Barzon 2010
[55]
Italy Glans/Corona, penile
shaft, urethra
Males presenting for screening for STDs,
investigation of suspected HPV-related lesions, or
because of HPV-positive partners
947 Swabs
PCR
Glans/
corona:
43.3
Penile
shaft:
58.3
Urethra:
31.0
Semen:
23.9
(39.0-47,6)
(47.8-68.3)
(25.6-36.5)
(19.0-28.8)
12.2
9.4
7.3
5.6
(9.32-15.0)
(4.38-17.05)
(4.2-10.4)
(18.9-28.8)
Kataoka,
1991 [32]
Sweden Urethra Army conscripts 105 Brushing
PCR
17.1 (9.9-24.4)
Hillman,
1993 [61]
United
Kingdom
Urethra
Urine
STD clinic attendees 100
urethra
samples
88 urine
specimen
Cotton-tipped swabs
Urine sample
PCR
Urethra:
18.0
Urine:
12.5
(10.5-25.5)
(5.6-19.4)
Urethra:
12.0
Urine:
9.1
(5.6-18.4)
(3.1-15.1)
Aynaud,
2002 [53]
France Semen Men with normal peniscopy whose female partners
have genital HPV lesions
46 Ejaculate
PCR
2.2 (0-6.4) NI
Aynaud,
2003 [62]
France Meatal-urethral smears Men with normal peniscopy whose female partners
have genital HPV lesions
34 Brushing
PCR
2.9 (0-8.4) NI
Giovanelli,
2007 [63]
Italy Penile shaft, foreskin,
coronal sulcus, frenulum,
glans, semen
Partners of HPV-positive women 50 Cotton-tipped swab,
cytobrush, ejaculate
PCR
72.0 (59.6-84.4) 56.0 (42.2-69.8)
Benevolo,
2008 [64]
Italy Penile shaft, prepuce,
coronal sulcus, glans,
distal urethra
Male partners of women with CIN and/or positive
HPV
71 Cytobrush
PCR
35.2 (24.1-46.3) 31.0 (20.2-41.7)
Bleeker, 2004
[65]
The
Netherlands
Glans, corona, sulcus,
frenulum, foreskin
Men with female partners, visiting department of
dermatology for non-STD complaints
83 Brushing
PCR
25.3 (15.9-34.7) 19.3 (10.8-27.8)
Castellsagué,
1997 [66]
Bosch, 1996
[67]
Spain Intrameatal and distal
urethra, glans, coronal
sulcus
Male partners of women with cervical cancer 183 Cotton-tipped swabs 17.5 (12.0-23.0) 15.8 (10.6-21.1)
Male partners of control women 171 3.5 (0.8-6.3) 2.3 (0.1-4.6)
Voog, 1997
[68]
Sweden Glans penis, prepuce STD clinic attendees 20 Cytobrush 25 (6.0-44.0) NI
Strand, 1993
[69]
Sweden Urethra, glans penis,
sulcus, preputium, penile
shaft
STD clinic attendees 65 Plastic probe +
cytobrush
29.2 (18.2-40.3) NI
CI confidence interval, CIN cervical intraepithelial neoplasia, MSM men who have sex with men, HS heterosexual, STD sexually transmitted disease
a 26 European countries
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8Moreover, the majority of HPV-positive cancers in men
are attributable to oncogenic HPV16/18, while the great
majority of genital warts and virtually all cases of recur-
rent respiratory papillomatosis are caused by HPV6/11.
In this report, a total of 72,694 new HPV-related can-
cer cases were estimated to occur each year in men in
Europe. Moreover, we estimated that 17,403 of these
cancers could be attributable to HPV, of which 15,497
were estimated to be specifically attributable to HPV16/
18.
In addition, between 335,301 and 380,961 new cases
of genital warts were estimated to occur annually in
men in Europe, with 286,682-325,722 of them attributa-
ble to HPV6/11.
Recurrent respiratory papillomatosis is a very rare dis-
ease and incidence data in Europe are scarce. It was not
possible to estimate the number of new annual cases in
men in Europe. Nevertheless, the association with HPV
is particularly strong for this disease, and virtually all
cases are attributable to HPV6/11 [70].
HPV-related cancers
Head and neck cancers
There was high variability in the incidence of head and
neck cancers, irrespective of HPV status, with age-stan-
dardised incidence rates in Europe ranging from 5.6 to
33.0 per 100,000 man-years. The distribution of the sub-
set of head and neck cancers included herein also varied
throughout Europe. This may be partially due to regio-
nal differences in HPV prevalence, which are in turn
related to differences in the distribution of risk factors
for HPV infection, such as sexual behaviour. It may also
be due to differences in the distribution of non-HPV-
related risk factors like alcohol consumption and
tobacco use, which explain some 80% of these cancers.
Large cohort studies from Sweden show increasing
evidence of a steady rise in the incidence of a subset of
cancers of the oral cavity (especially lateral border of the
tongue) [71] and oropharynx (notably tonsillar and base
of the tongue [22,23,71,72]). In these studies oropharyn-
geal cancer was most strongly associated with HPV. The
overall HPV detection rate in tonsillar carcinoma
r e a c h e du pt o5 1 % ,w i t hH P V 1 6b e i n gt h em o s tc o m -
mon type (84%) [71,73,74]. The increasing trend may be
d u et oa ni n c r e a s eo fH P Vi n f e c t i o n si nt h eh e a da n d
neck, possibly related to changes in sexual behaviour.
Anal cancer
An overall number of 2,162 annual cases were estimated
to occur in men in Europe, irrespective of HPV status
and the association of anal cancer with HPV is extre-
mely strong (84.2% HPV-related) [19].
An increasing trend in the incidence of anal cancer
has been reported for a number of countries, including
Denmark [25], Sweden [27], the Netherlands [28] and
the United Kingdom [24]. Regional differences in inci-
dence could be explained by regional differences in anal
HPV prevalence, the key causal precursor for anal can-
cer [75], and its associated causes and consequences,
such as history of condyloma [76], history of anorecep-
tive intercourse [76,77] and increased lifetime number
of sexual partners [78].
Penile cancer
Three thousand one hundred seventy-eight new penile
cancer cases, irrespective of HPV status, were estimated
to occur yearly in Europe with almost half of these cases
(1,484) attributable to HPV.
In addition to regional differences in penile HPV pre-
valence, differences in the incidence of penile cancer
may be due to differences in the regional distribution of
risk factors that are not related to HPV infection, such
as smoking, phimosis and absence of circumcision
[79,80].
HPV-related non-malignant diseases
Genital warts
The burden of genital warts in men in Europe is sub-
stantial. Extrapolated from the most robust European
incidence data collected in Germany and in the United
Kingdom, new cases were estimated to range between
335,301 and 380,961 in men in Europe every year. The
vast majority are estimated to be attributable to HPV6/
11. As for HPV-related malignant diseases, the incidence
of genital warts varies highly by geographical region.
This may be due partially due to differences in the dis-
tribution of risk factors for HPV infection. Furthermore,
there is some evidence of a steady rise of genital warts
in men in the United Kingdom [81].
Genital warts are not life-threatening, but they are
associated with high morbidity: psychosocial stigma, psy-
chosexual dysfunction, depression and lower quality of
life [82,83]. Treatment is painful, and there is a high risk
of recurrence.
Recurrent respiratory papillomatosis
In Europe, only two studies provided data on the inci-
dence of recurrent respiratory papillomatosis in both
sexes: 0.35-0.38 per 100,000 person-years. There was no
specific information about incidence in men but the sex
ratio for juvenile onset recurrent respiratory papilloma-
tosis was reported to be 1:1, while there was a pro-
nounced male preponderance in onset in adulthood
[42].
Virtually 100% of cases are caused by HPV, the most
common types being HPV6/11 [11]. Maternal condy-
loma or genital HPV infection during pregnancy is the
overwhelming risk factor for juvenile onset recurrent
respiratory papillomatosis (more than 200-fold increased
risk) [43,70]. Although non-malignant, the disease is
associated with very high morbidity. It has the potential
Hartwig et al. BMC Cancer 2012, 12:30
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Page 13 of 18to be life-threatening and the number of lifetime sur-
geries may exceed 100 in children with severe disease
[70].
HPV infection
Head and neck
Overall HPV prevalence in the head and neck ranged
from 0 to 18% among men in Europe, and specific pre-
valence of all high-risk HPV types from 0 to 14.5%. Due
to the small number of European studies and the rela-
tively small sample sizes, these results must be consid-
ered with caution. More robust data are available when
worldwide studies are considered. Indeed, a systematic
review of all published studies worldwide (n = 18) that
detected HPV DNA in the oral cavity of 4,070 cancer-
free subjects found a pooled HPV prevalence (any type)
of 4.5% (95%CI: 3.9%-5.1%); the prevalence of high-risk
types was 3.5% (95%CI: 3.0%-4.1%) [84]. In a recent
study of 1,680 healthy men from the United States,
Mexico, and Brazil, HPV DNA was detected in the oral
cavity of 4.0% (95%CI: 3.1%-5.0%), and carcinogenic
HPV DNA in 1.3% (95%CI: 0.8%-2.0%) of subjects [85].
Anus
The prevalence of anal HPV infection in men in Eur-
opean studies ranged between 15.3% [49] and 94.1%
[50], but all these studies included presumably high-risk
populations and there were no data on the prevalence of
anal HPV infection in the general male population in
Europe.
Penis
The prevalence of penile HPV infection in men in Eur-
ope ranged from 2.2% (95%CI: 0.0%-6.4%) [53] to 72.9%
(95%CI: 65.8%-79.3%) [54]. The heterogeneity of the
published data is partly due to the use of different sam-
ple techniques, detection methods, anatomical sites or
specimens sampled, as well as study populations with
different risk factors. The penis is made up of different
types of body tissue, which differ in their susceptibility
to HPV infection. Data from literature have indicated
that the prepuce has the highest proportion of HPV-
positive samples, though reports have also shown an
increase in HPV DNA detection when multiple anato-
mical sites were sampled [86].
Most of the studies that evaluated the prevalence of
HPV infection in anogenital sites included high-risk
populations. Nevertheless, data from the United States
have shown a very high prevalence of anogenital HPV
infection (65%) in population-based studies [87,88]. The
incidence of new genital HPV infections in this popula-
tion was 38.4 per 1,000 person months (95%CI: 34.3-
43.0) in a recent study including men aged 18-70 years
with a median duration of HPV infection of 7.52
months (95%CI: 6.80-8.61) for any HPV infection and
12.19 months (95%CI: 7.16-18.17) for infection with
HPV16 [89].
In addition, a recent global review of the age-specific
prevalence of HPV infection in men [86] identified 64
abstracts with data on genital HPV infection in men
worldwide, including 38 from populations at high risk of
HPV infection. The authors of the study concluded that
the risk of HPV infection is generally high for most men
in many geographical areas, with comparable prevalence
in both low-risk (1-84%) and high-risk populations (2-
93%).
Little is known about the natural history of HPV
infection in men. Few studies have prospectively
assessed HPV infection, and therefore few data are avail-
able on the incidence, acquisition and persistence of
HPV infection in men. A recent review on HPV preva-
lence in men concluded that, in contrast to results for
women, age-specific prevalence curves remained rela-
tively flat with age, or declined only slightly with post-
peak prevalence. Thus, men may potentially have more
long-term persistent HPV infections, or a higher rate of
re-infection [86].
Comparison to the burden in women
For comparison purposes, the methods described above
were also used to estimate the epidemiological burden
of HPV-related cancers and genital warts in women in
Europe. Using our methods of estimation, a total of
32,562 cancer cases specifically due to HPV16/18 were
expected to occur in women in Europe every year. The
new annual number of cases of genital warts attributable
to HPV6/11 in women in Europe was estimated to
range between 288,959 and 388,873.
A total of 48,059 HPV16/18-positive cancer cases were
estimated to occur annually in Europe in both sexes, of
w h i c hm o r et h a n3 0 %o c c u ri nm e n( T a b l e8 ) .O t h e r
than cervical cancer, 23,254 annual cases of which are
estimated to be HPV16/18-positive, the estimated bur-
den of cancer cases attributable to HPV is higher in
men than in women, and is mainly driven by head and
neck cancers.
The incidence of head and neck cancers attributable
to HPV16/18 is five-fold higher in men (12,707 new
cases yearly) than women (2,531 new cases yearly). In
addition, new cases of genital warts attributable to
HPV6/11 in both genders were estimated to range
between 614,681 and 675,555 yearly in Europe, half of
them affecting men.
Impact of HPV vaccination
The preliminary effects of HPV vaccination on genital
warts and precancerous lesions have been reported from
Australia, where a vaccination programme using the
Hartwig et al. BMC Cancer 2012, 12:30
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showed that in addition to a significant decline in the
number of cases of genital warts and in the incidence of
high-grade cervical abnormalities among young women
in Australia, the number of cases of genital warts among
heterosexual men also declined markedly [90].
Limitations
Our report has several limitations. A short-term prediction
method was used to estimate the expected number of inci-
dent cancer cases in 2008 from the most recent data col-
lected from 1998 to 2002. Therefore these predictions were
accurate only if the disease rates remained stable over time.
In the case of an increasing trend, they would slightly
underestimate the expected number of cases, and the
opposite would be true in the case of a decreasing trend.
As mentioned above, the CI5 database contains
national cancer incidence rates for 17 European coun-
tries. For the remaining nine countries included in this
report only regional incidence rates were available in the
CI5 database. Although we assessed the geographical
coverage and distribution of these regional registries,
other non-controllable factors, like differences in alcohol
and tobacco consumption, could vary and influence
regional incidence rates. The results should thus be
interpreted with particular caution.
T h ep r e s e n c eo fH P VD N Ai su s e dt oc a l c u l a t et h e
prevalence of HPV in a given population. However the
mere presence of HPV is insufficient to prove causation,
as the infection may be transient and not related to the
carcinogenic process. Therefore our application of pre-
viously published HPV prevalence to an estimated num-
ber of new cancer cases may have yielded an
overestimation of cases attributable to HPV infection.
Finally, the prevalence of HPV16/18 co-infections has
not been evaluated, thus summarising HPV16/18 preva-
lence may have led to an overestimation of the cancer
burden attributable to these types.
Another limitation is the absence of sex-specific HPV
prevalence data in anal and head and neck cancers.
Consequently, our report assumed that HPV prevalence
is the same in both sexes. Currently, we have no reliable
data that would confirm this hypothesis, and it seems to
be inconsistent with the worldwide data from the meta-
analysis by De Vuyst et al. [19], which showed a higher
HPV prevalence in anal carcinoma among women
(90.8%) than men (74.9%). To our knowledge, sex-speci-
fic data on HPV prevalence in head and neck cancers
are lacking, and future research is needed.
We applied the same HPV prevalence to all European
countries in this report. However, regional differences in
HPV prevalence could exist, notably due to the fact that
in some countries other non-HPV-related risk factors, i.
e., tobacco or alcohol consumption may predominate.
Furthermore, when type-specific HPV data for Europe
was lacking, we used worldwide data, thus assuming
that there is no difference in the HPV16/18 distribution
between Europe and other parts of the world.
The method used to estimate the expected annual
number of new genital wart cases attributable to HPV6/
11 has also some limitations. We based our estimations
on incidence data extracted from only two studies and
only one of them was population-based [17]. In addi-
tion, due to the lack of data, it was not possible to
extrapolate incidence data per age, but only by sex.
However, there may be important differences in the age
structure of European countries. Also, the incidence of
genital warts throughout Europe may vary, due to regio-
nal differences in the prevalence of HPV infection and
its underlying risk factors.
Conclusions
A total of 15,497 new cancer cases attributable to
HPV16/18, and between 286,682 and 325,722 new cases
of genital warts attributable to HPV6/11, were estimated
to occur yearly in men in Europe.
The burden of HPV-related cancer in men is higher
than generally perceived and is primarily driven by head
and neck cancers. There is currently no routine screen-
ing for HPV-related cancers in men, and head and neck
Table 8 The burden of new yearly human papillomavirus (HPV)16/18-related cancers in men vs. women in Europe
a
Anatomical site (ICD-10 code) Men Number of new yearly cases (% of
overall burden in both sexes)
Women Number of new yearly cases (% of
overall burden in both sexes)
Cervix uteri (C53) 0 (0) 23,254 (48.4)
Head and neck (C01-C02, C03-C06, C09,
C10, C12, C13, C14 and C32)
12,706 (26.4) 2,531 (5.3)
Anus (C21) 1,700 (3.5) 2,929 (6.1)
Vulva (C51) 0 (0) 2,702 (5.6)
Vagina (C52) 0 (0) 1,146 (2.4)
Penis (C60) 1091 (2.3) 0 (0)
Total 15,497 (32.2) 32,562 (67.8)
ICD International Classification of Diseases
a 26 European countries
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Page 15 of 18cancers in particular are associated with very high mor-
bidity. In addition, there is some evidence of a steady
rise of the incidence of HPV-related cancers and genital
warts.
The high proportion of HPV-positive cancers attribu-
table to HPV16/18, and of non-malignant diseases attri-
butable to HPV6/11, underscores the potential to
prevent the majority of HPV-related diseases among
men through prophylactic vaccination with the quadri-
valent HPV vaccine. Further research is needed to evalu-
ate the efficacy of prophylactic HPV vaccines at non-
cervical sites in men and women.
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